In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

• Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
• Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
• Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:

• An overview of ADC structure and mechanism of action
• A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
• An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies

Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy.

Program faculty:

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
UK HealthCare
Markey Cancer Center
Lexington, Kentucky

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Program page:
https://bit.ly/4lr7cT6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:

• The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)
• Cough as the most significant symptom and burden
• Imaging bronchiectasis with classic and inflammatory findings
• Differentiating the causes of NCFBE to inform patient care

Presenters

Brett M. Elicker, MD
Professor of Clinical Radiology
Chief, Cardiothoracic Imaging Division
Department of Radiology & Biomedical Imaging
University of California, San Francisco
San Francisco, California

David E. Griffith, MD, ATSF, FACCP, FRSM
Professor of Medicine
Division of Mycobacterial and Respiratory Diseases
Department of Medicine
National Jewish Health
Denver, Colorado

Program page:
https://bit.ly/4mZbYsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.